BC Extra | Jan 13, 2020
Clinical News

Adaptimmune rises on early promise for SPEAR TCR cell therapies in solid tumors

Cancer cell therapy play Adaptimmune gained $2.66 (200%) to $3.99 on Monday after announcing a new set of data for its SPEAR T cell therapies in four different solid tumor indications. The announcement by Adaptimmune...
BC Extra | Aug 2, 2019
Clinical News

Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma  AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the...
BC Extra | May 9, 2019
Company News

bluebird to rollout Zynteglo starting in Germany next half

bluebird expects to launch β-thalassemia gene therapy Zynteglo in Germany next half, followed by launches in Italy, France and the U.K. in 2020. In March, EMA's CHMP recommended conditional approval of Zynteglo to treat transfusion-dependent...
BC Innovations | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
BC Week In Review | Nov 30, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

Despite losing at least five key executives this year, Immunocore Ltd. (Abingdon, U.K.) has teamed up with Genentech Inc. to advance the first soluble TCR-based therapy from their existing deal into clinical testing for solid...
BC Extra | Nov 19, 2018
Company News

Immunocore, Genentech team up to bring soluble TCR therapy into clinic

Despite losing at least five key executives this year, Immunocore Ltd. (Abingdon, U.K.) has teamed up with Genentech Inc. to advance the first soluble TCR-based therapy from their existing deal into clinical testing for solid...
BC Week In Review | Oct 26, 2018
Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the company's MAGE-A10 and MAGE-A4 SPEAR T cell therapies...
BC Extra | Oct 22, 2018
Clinical News

Adaptimmune reports zero responses across three T cell therapy trials

Adaptimmune Therapeutics plc (NASDAQ:ADAP) fell $3.21 (30%) to $7.55 on Monday after reporting that zero of 17 evaluable patients achieved a response across the first two dose cohorts of three Phase I trials evaluating the...
BC Week In Review | May 18, 2017
Clinical News

Adaptimmune’s T cell therapy against MAGEA4 enters Phase I in solid tumors

Adaptimmune Therapeutics plc (NASDAQ:ADAP) began a Phase I trial to evaluate escalating doses of MAGE A4 TCR (MAGE-A4 SPEAR T-cell therapy, MAGEA4 TCR) in about 32 patients who are HLA-A*02-positive with locally advanced, inoperable or...
Items per page:
1 - 9 of 9